Almirall’s Phase 1 Study on LAD191: A Potential Game-Changer in Autoimmune Treatment

Almirall SA (GB:0O9B) announced an update on their ongoing clinical study.

Almirall SA has recently completed a Phase 1 clinical study titled A Phase 1 Randomized, 3-Part, Placebo-Controlled, Single Ascending and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of LAD191 in Healthy Subjects and Subjects With an Autoimmune Disease. The study aimed to evaluate the safety and tolerability of LAD191, a new drug intended for autoimmune diseases, in both healthy participants and those with an autoimmune condition.

The study tested LAD191, a subcutaneous injection, in various doses to assess its safety and effectiveness. Participants received either a single or multiple ascending doses of LAD191 or a placebo, depending on the cohort they were in.

This was a randomized, placebo-controlled study conducted in three parts. It involved a sequential intervention model with single and double-blind masking to ensure unbiased results. The primary goal was to evaluate the treatment’s safety and pharmacological profile.

The study began on June 28, 2024, and its primary completion was achieved by November 21, 2025. These dates are crucial as they mark the timeline for data collection and analysis, which influences the drug’s development and potential market release.

The completion of this study could positively impact Almirall’s stock performance, as successful results may lead to further development and commercialization of LAD191. This could enhance investor confidence, especially in the competitive autoimmune disease treatment market.

The study is now completed, and further details can be accessed on the ClinicalTrials portal.

To learn more about GB:0O9B’s potential, visit the Almirall SA drug pipeline page.